Artículo de revista
Humoral immune response of BNT162b2 and CoronaVac vaccinations in hemodialysis patients: a multicenter prospective cohort
Fecha
2022Registro en:
Vaccines 2022, 10, 1542
10.3390/vaccines10091542
Autor
Clavero, René
Parra Lucares, Alfredo Andrés
Méndez Valdés, Gabriel Andrés
Villa, Eduardo
Bravo Espinoza, Karin Constanza
Mondaca, Evelyn
Aranda, Josseline
Brignardello, Rose
Gajardo, Cynthia
Ordenes, Angélica
Colombo, Evelyn
Tapia, Jessica
Etcheverry, Andoni
Zúñiga, José
Toro Cabrera, Luis Alejandro
Institución
Resumen
The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2. End-stage renal disease (ESRD) patients have an increased rate of COVID-19 and a reduced immune response to vaccinations. Currently, there is little data on this population's immune response induced by CoronaVac. Methods: This study involved a prospective cohort of ESRD patients in chronic hemodialysis who received a two-dose immunization scheme of either CoronaVac (Sinovac Biotech) or BNT162b2 vaccines (Pfizer-BioNTech). We measured the plasma levels of anti-SARS-CoV-2 IgG antibodies. We determined antibody titers before immunization, 2 and 4 months after two doses, plus 4 months after a booster dose. Results: We evaluated 208 patients in three hemodialysis centers. The mean age was 62.6 +/- 15.6 years, of whom 91 were female (41.75%). Eighty-one patients (38.94%) received the BNT162b2 vaccine and 127 (61.06%) received the CoronaVac vaccine. Patients who received the BNT162b2 vaccine had a higher humoral response compared to those who received the CoronaVac vaccine (4 months after the second dose: BNT162b2: 88.89%, CoronaVac: 51.97%, p < 0.001; 4 months after the booster: BNT162b2: 98.77%, CoronaVac: 86.61%, p < 0.001). Conclusions: Our results suggest that the CoronaVac vaccine induced a lower humoral response than the BNT162b2 vaccine in ESRD patients on hemodialysis.